argenx’s Post

I am proud of the Phase 3 data #MyCompany, Johnson & Johnson Innovative Medicine presented at the 2024 European Academy of Neurology Meeting. For patients with generalized myasthenia gravis (gMG), a chronic, rare autoantibody-driven disease, more effective treatment options are crucial for improving quality of life. My colleagues and I are driven to address the remaining unmet needs in this space, and we are grateful to have collaborated with other industry experts who share this passion for purposeful scientific exploration at #EAN2024.    #JNJNeuroscience #JNJImmunology 

Can't we increase not find a solid state electrolyte that would act as a reducer for depolarization of cell membrane like the new lithium batteries? I don't really know anything about science, but I like to imagine possibilities. 😀 #houseoflovingawareness #coloradomentalwellnessinitiative #willojontv #neurology #science #mentalhealth #mentalhealthmatters #mentalwellness #americanspiritsthemovie

🧠✨ Dive into the fascinating world of neurology at the Global Neurology Summit 2024! 🌍🔬 This eMedEvents blog uncovers the details of this hybrid event focusing on innovative therapies for neurological disorders - https://bit.ly/43CEGWI 🏥📝This conference, organized by eMedEd, promises to be a transformative experience, bringing together neurologic experts from around the globe to collaborate and advance patient care. #NeurologyConference #GlobalSummit #MedicalEducation #emedevents #cmeconferences #medicalconferences #eMedEvents

Results from our Phase 2 Vivacity-MG study evaluating nipocalimab in adults with moderate-to-severe generalized myasthenia gravis were published in Neurology by the American Academy of Neurology. These results reinforce our path to progress in offering safer, more effective and tolerable treatment options to people living with this rare autoantibody disease of the nervous system.   I want to extend my gratitude to our dedicated research team and to our clinical trial participants, without whom we could not advance the science towards better therapeutics. Access the article here: https://bit.ly/3NCoRZp #MyCompany #MyastheniaGravis

February 29 is #RareDiseaseDay. Learn more about rare diseases in neurology through CNSA's Clinical Proceedings series ▶️ https://bit.ly/3a2xoEh

CHKD offers the latest treatments for children with Duchenne muscular dystrophy. In this video, Director of Neurology Crystal Proud, MD, discusses the signs and symptoms of Duchenne's as well as a new treatment offered at #CHKD. #DuchenneMuscularDystrophy #Elevidys

Neuroanatomic correlates of IUO

Intense basics of neurology Session 12: 22/06/2024 Topics: 1. Motor neuron 2. Motor neuron diseases 3. Spinal nerve formation 4. Dermatome and Myotome Timing: 8:20pm-9:40pm

latest clinical guidelines 🛑☑️⬇️ Cluster Headache Clinical Practice Guidelines (EAN, 2023) European Academy of Neurology. For the acute treatment of cluster headache attacks, oxygen (100%) with a flow of at least 12 L/min over 15 min and 6 mg subcutaneous sumatriptan is strongly recommended. Verapamil at a daily dose of at least 240 mg (maximum dose depends on efficacy and tolerability) is recommended for prophylaxis of cluster headache attacks. The use of at least 100 mg prednisone (or equivalent corticosteroid) given orally or at up to 500 mg iv per day over 5 days is recommended to reach an effect in cluster headache. For episodic cluster headache only, lithium, topiramate, and galcanezumab are recommended as alternative treatments. reference #medscape

Interesting approach: Listening to neurologic footfall.